ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,969.34
0.35%
US Tech 100
20,266.40
0.33%
다우존스 지수
44,296.51
0.97%
Bitcoin
0.00000000
0.00%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Capricor Therapeutics Inc (CAPR) 시세

Capricor Therapeutics Inc

Capricor Therapeutics Inc (CAPR)

Caprock Mining Corp
18.62
0.83
(4.67%)
마감 25 11월 6:00AM
15분 지연
18.50
-0.12
(-0.64%)
시간외 거래: 9:59AM
15분 지연

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

주요 통계 및 세부정보

가격
18.50
매수가
18.20
매도가
18.45
거래량
1,004,452
17.5133 일간 변동폭 18.8799
2.90 52주 범위 23.40
market_cap
841.193M
전일 종가
17.79
개장가
17.94
최근 거래 시간
954
@
18.5
(formt)
마지막 거래 시간
재정 규모
US$ 18,209,676
VWAP
18.129
평균 볼륨(3m)
3,355,420
발행 주식
45,469,908
배당수익률
-
주가수익률
-37.96
주당순이익(EPS)
-0.49
매출
25.18M
순이익
-22.29M

Capricor Therapeutics Inc 정보

Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell t... Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.capricor.com
본부
Wilmington, Delaware, USA
설립됨
-
Capricor Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker CAPR. The last closing price for Capricor Therapeutics was US$17.79. Over the last year, Capricor Therapeutics shares have traded in a share price range of US$ 2.90 to US$ 23.40.

Capricor Therapeutics currently has 45,469,908 shares in issue. The market capitalisation of Capricor Therapeutics is US$808.91 million. Capricor Therapeutics has a price to earnings ratio (PE ratio) of -37.96.

Capricor Therapeutics (CAPR) 옵션 플로우 요약

전체 옵션 플로우 보기

전체 흐름

약세

순 프리미엄

-170k

Calls / Puts

0,00%

매수 / 매도

100,00%

OTM / ITM

0,00%

Sweeps 비율

0,00%

CAPR 최신 뉴스

추가 뉴스

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...

20 11월 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

15 11월 2024
Edgar (US Regulatory)

Form 8-K - Current report

14 11월 2024
Edgar (US Regulatory)

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Announced intent to file a biologics license application (BLA) for deramiocel to treat all patients with DMD-cardiomyopathy Rolling BLA submission initiated in October 2024 with full submission...

14 11월 2024
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

13 11월 2024
Edgar (US Regulatory)

Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...

12 11월 2024
GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness

12 11월 2024
Edgar (US Regulatory)

Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...

05 11월 2024
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

25 10월 2024
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

23 10월 2024
Edgar (US Regulatory)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.382.0971302428318.1220.0317.02115803018.27625025CS
4-3.09-14.312181565521.5922.916.77113353319.14188061CS
1213.79292.7813163484.7123.43.98335542014.35186951CS
2612.21194.1176470596.2923.43.52176616213.15626066CS
5215.52520.8053691282.9823.42.9104375312.03269818CS
15615.22464.0243902443.2823.42.5646698810.05092447CS
26016.69922.0994475141.8123.40.888942957.39453566CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PDYNPalladyne AI Corporation
US$ 4.59
(129.50%)
83.07M
QMCOQuantum Corporation
US$ 9.11
(126.62%)
39.48M
NANano Labs Ltd
US$ 8.26
(89.02%)
2.03M
XCURExicure Inc
US$ 18.60
(71.27%)
4.59M
SKKSKK Holdings Limited
US$ 1.75
(59.09%)
107.47M
AMIXAutonomix Medical Inc
US$ 6.21
(-54.07%)
946.09k
CETXCemtrex Inc
US$ 0.1146
(-41.74%)
24.39M
MSWMing Shing Group Holdings Ltd
 5.90
(-35.52%)
417.08k
RMSGReal Messenger Corporation
US$ 3.09
(-26.25%)
313.51k
ENSCEnsysce Biosciences Inc
US$ 0.4414
(-25.49%)
4M
ELABElevai Labs Inc
US$ 0.0201
(-0.50%)
425.38M
NVDANVIDIA Corporation
US$ 141.95
(-3.22%)
236.51M
SMCISuper Micro Computer Inc
US$ 33.15
(11.62%)
159.61M
VRPXVirpax Pharmaceuticals Inc
US$ 0.5501
(-6.72%)
159.39M
SOUNSoundHound AI Inc
US$ 8.24
(18.05%)
107.91M

CAPR Discussion

게시물 보기
Mionaer1 Mionaer1 5 일 전
https://d1io3yog0oux5.cloudfront.net/_a2273a855b16264d98c228e2a432c4ee/capricor/news/2024-11-20_Capricor_Therapeutics_Granted_Orphan_Drug_and_301.pdf

Great news.
👍️0
Mionaer1 Mionaer1 1 주 전
Trading range $17-22 IMO. When BLA ready (end of 2024) $30 IMO.
👍️ 1
ed3/6me ed3/6me 1 주 전
Thought it would've 17 so close. Only have pennies so can't buy much but figure the next level and 23/24. Down to 19/20 then bumping up past 30
👍 1
GreedyAgorist GreedyAgorist 2 주 전
Looks like you nearly nailed that floor price.

So, the first reaction to the quarterly numbers makes sense: down on still no P/E ratio (i.e., negative earnings). And then a bounce, presumably thanks to bargain hunters who think that if 20 is a bargain, then 17 is a steal.

We seem to be settling in price-wise. It's not just FOMO* up like last month, although we can, with some regularity, still get 10-15% swings either way to keep it interesting. For options traders like me, who, before the FDA/BLA news, have been buying under 5 and selling covered calls (mostly at 5, with the occasional 7.5 thrown in there) the only question is: What is the new 5? 20 or 17.50?

*with a little BTFD mixed in
👍️0
Laster Laster 4 주 전
Excellent that $21 support held. I was nervous for a little bit.
Now let’s break $22.50 so we can have clear sailing to $30 with target $35.
I am confident (sort of) that this will occur.
Here’s hoping.
👍 1
Laster Laster 4 주 전
Failed $22.50 break multiple times.
Probably time to consolidate before next run.
Might drop and find support at $19.50.
Hopefully not.
Still looking and hoping for volume to power this past $22.50 for good.
👍️0
Laster Laster 4 주 전
The stock chart is showing a nice ascending triangle from Sept 30th breakout from $10.
Using my novice chart skills, I get a target of $35 for the stock (flag pole from $10 to resistance at $22.50 = $12.50).
$22.50 plus $12.50 = $35. Sounds good to me.
Lower trendline has shown nice support but if the stock moves back to $20 then stock might drop back to $17.50.
Let’s what happens this week.
Hoping for move to $25 if the market looks good.
👍️0
staynafloat staynafloat 4 주 전
I think what helped the most is that the OS is only 44.7 Mil. with that added in. It appears that a lot of traders are holding making it trade very thin.

LOL ... I've been waiting for almost 5 years for this to go thru all the trials and testing and it sure is sweet :)
👍️0
GreedyAgorist GreedyAgorist 4 주 전
That dilution went about as well as any I’ve seen. The news did not even bring us below 18 for more than a wick or two. Correct me if I’m wrong, but the underwriters made out quite well, at least an extra dollar per additional share issued (~5M). Nice work if you can get it.
👍️0
Laster Laster 1 월 전
Sounds good.
Hopefully yesterday was a technical sell off to show $20 support level.
Maybe get rid of those low hanging stop loss orders.
I am not worried about another financing so I expect a nice move to $25 then $30 by EOY.
Enjoy.
👍️0
XWAVXALMIMAN XWAVXALMIMAN 1 월 전
No comment on Blackrock report owning over 5% of Capricor?
30 will be here soon. Maybe a short squeeze will pop us up to 40
👍️0
Laster Laster 1 월 전
You never know but these $20 stocks tend to move to $25 or even $30.
I wouldn’t mind a nice 25% profit here.
👍️0
Volcano Volcano 1 월 전
The small float is getting locked up by big boys everyday
My prediction $30 by Thanksgiving and $50 by Christmas and $100 upon FDA approval in early next year
Thus became the millionaire stock indeed
👍️0
Mionaer1 Mionaer1 1 월 전
Piper Sandler PT $35

Piper Sandler analyst Edward Tenthoff initiates coverage on Capricor Therapeutics (NASDAQ: $CAPR) with an Overweight rating and a price target of $35.00.

The analyst comments: "Capricor is developing deramiocel (CAP-1002) to treat cardiomyopathy in Duchenne Muscular Dystrophy (DMD) boys. In the Phase II HOPE-2 trial (N=20), deramiocel slowed LVEF decline by 107% vs. placebo at 12 months. (p=0.002) At World Muscle Society, HOPE-2 OLE data showed deramiocel achieved an 8.1 point improvement in median LVEF and 11.0ml/m2 benefit in median End Systolic Volume vs. external controls at 2 years with benefit maintained out to 3 years. Capricor has begun the rolling BLA submission, and deramiocel could gain FDA approval for DMD cardiomyopathy in 2H:25. Deramiocel is partnered globally with Nippon Shinyaku with Capricor retaining 30-50% of potential blockbuster revenues, plus up to $1.5 billion in milestones. Capricor recently issued 5.1 million shares at $17 raising gross proceeds of $86 million, bringing pro forma cash to ~ $198 million excluding 3Q:24 burn."
👍️0
ed3/6me ed3/6me 1 월 전
time will tell
👍️0
Mionaer1 Mionaer1 1 월 전
$12? Never. $17 is the new floor IMO.
👍️0
ed3/6me ed3/6me 1 월 전
My thought is slide back to 12-15 then move to 21-25. Dip again then about 20%up. Never straight unless flooring news
👍️0
Volcano Volcano 1 월 전
This beast will keep moving up in the coming days
FDA approval is guaranteed and secured huge fund
I expect $50 by Christmas and $100 next year
I am a millionaire here
👍️0
GreedyAgorist GreedyAgorist 1 월 전
Looks like they are not even asking enough for them.

"Capricor Therapeutics (CAPR) said Thursday that it priced an underwritten offering of about 4.4 million shares at $17 per share..."

I knew the dilution was coming. I guess I was hoping that news would be later, not this week. Like the earnings report that will be a negative number (but not as negative as last quarter).

Dips are buying opportunities, but when they are based on fundamental rules of supply and demand, I wonder if there is a hurry any more. Need to know what the new plateau is. Again, I guess it was too much to ask for that to be established after this week.

: - }
👍️0
XWAVXALMIMAN XWAVXALMIMAN 1 월 전
It looked like we would hold at 20. Then they diluted our shares. I hate when that happens. Didn’t they have enough cash to survive until we would be profitable? Hopefully good news is coming and that extra money will be used for growth
👍️0
GreedyAgorist GreedyAgorist 1 월 전
Arrgghh, they could not wait to dilute, huh? I just needed a couple more days.

Feels like somebody got the info early, too. I have to wonder what price they are getting. Today's high? The after hours' low?
👍️0
ed3/6me ed3/6me 1 월 전
They sell today? Would be another k in your pocket
👍️0
XWAVXALMIMAN XWAVXALMIMAN 1 월 전
Great day today. We started out down and then reversed and had trouble getting thru 20. Since I was having eye surgery today, I put in to sell 7250 shares at 20.20. It looked good for a while when we went down to low 19’s. I tried to buy back at 18.65 but never got there. This was my 3rd time selling and buying back and selling again. I’m done. Keeping my 40.000 shares until we get to 30-40.

We ran up to 23.40 before some profit taking. Some of you are looking for a 10% correction. I use Fibonacci numbers / Elliott Wave.
We went from 4 to 22 which is 18 and then went down to around 15; a 7 point retracement. 7/18 is around 38%.

Next Wave took us from 15 to 23+. Going up 8 points means that selling should take us down 3. Expect support at 20 before the next big up move.Have a great week. Let’s Go Mets and Guardians!
👍️0
D-bol D-bol 1 월 전
DRUG We need a move like this one today!!
👍️0
D-bol D-bol 1 월 전
I’m with you
👍️0
Volcano Volcano 1 월 전
Yep
Still waiting for $100 Pps
👍️0
D-bol D-bol 1 월 전
Volcano are you still here? Haven’t heard from you in a while.
👍️0
GreedyAgorist GreedyAgorist 1 월 전
Just another day at the office with Capricor. Up 15%+ again. Do we get the 10% sell off before resuming the climb? That would still be a respectable gain of 7.5%. If we close above 22, that will be rarefied air for anyone in this for less than 6 years. Held the 21 handle briefly two weeks ago.

I have already played a couple of dips this week. Now waiting for a legitimate correction.
👍️0
XWAVXALMIMAN XWAVXALMIMAN 1 월 전
Thanks Ed. I tried to sell 7250 at 19.80 which I had bought at 18.80. Still holding my 40,000 shares.
I’m buying some XRP with my profits and averaging down on some of my other losers. taking out some cash for vacations
👍️0
TechandBio TechandBio 1 월 전
Next leg up will come in time patience!

$CAPR
👍️0
ed3/6me ed3/6me 1 월 전
agree. think retracement over till 25-30 range then probably 20% retract. but for the most part your bulk idea is solid. using 20-25% of your shares is a good way to hedge and try to get free shares. You already have profit so use it.
👍️0
XWAVXALMIMAN XWAVXALMIMAN 1 월 전
15.35 could be a good retracement of about 35% of the gain. We might retest that level but I wouldn’t risk it.
HC Wainwright raised their target from 40 to 70. I’m holding my core of 40,000 shares but I’m trading 7-10,000 shares for travel spending money. Planning a safari for my wife’s 70th. Sold over 20 twice and bought back at 17-18. If I can make 2-3 several times I’ll take it. If I sell and it never comes down for me to buy back, that’s fine too. I’ll still have my core. Good luck to everyone.
👍️0
GreedyAgorist GreedyAgorist 1 월 전
Day trading this one would have been fun. Actually, since there are only monthly options available on Capricor, I just sold a few more contracts expiring next week. I hardly ever buy options any more, although I did get into and out of a couple contracts expiring today on another ticker. Used the profit to cover the cost of a protective put here on this one. That should calm the nerves a bit next week as the expiration clock starts ticking louder. Not rooting for a down Monday, but if it comes, I will be ready.

Note to self: buy low, sell high.
👍️0
ed3/6me ed3/6me 1 월 전
You get in some day trade action?
👍️0
GreedyAgorist GreedyAgorist 1 월 전
Fun day: up 18% first thing in AM, then down 17%, only to recover 5%. If you only looked at the modest 3.8% green at the end of the day, you might have no clue as to the action. Unless, of course, you've been here for more than a few days.

; - )

Must remember to keep powder dry and trigger finger limber for another one like that.
👍️0
ed3/6me ed3/6me 1 월 전
Breather done. Told you16
👍️0
TechandBio TechandBio 1 월 전
Shorts runnning for the hills 101 LOL lets chop them up!

$CAPR
👍️0
TechandBio TechandBio 1 월 전
Sweet!

$40.00 Target!

$CAPR
👍️0
GreedyAgorist GreedyAgorist 1 월 전
Nevertheless, two days in a row of correction percentages was a bit much after almost all green for three weeks. Really three days of -10% if you start from the early morning top of Tuesday.

And as I type this, it seems to be bouncing quite strongly in the final hour or so. Will you accept 15.35 as low enough for that retracement?

: - )
👍️0
TechandBio TechandBio 2 월 전
Adding some vertical call debit spreads this morning for Q1 2025

$CAPR
👍️0
TechandBio TechandBio 2 월 전
Can't go straight up $40.00 Target in 2025 up 500%+ in 2024 was down 80% not that long big trend change.
$CAPR
👍️0
ed3/6me ed3/6me 2 월 전
Sounds right. You were smart if you sold out around 21. Buy back at 16
👍️0
XWAVXALMIMAN XWAVXALMIMAN 2 월 전
We went from 4 to 22, a gain of 18. If you follow Elliott Wave Theory and Fibonacci numbers, it would be normal to give back 38% of the gain before the next wave up. We should go down to 15.16 and then have a huge upward move up to 45.
👍️0
ed3/6me ed3/6me 2 월 전
people just taking profits. nothing new. as it drops it opens up new people to the company. does not hurt unless you sell in panic
👍️0
GreedyAgorist GreedyAgorist 2 월 전
Resistance hit yesterday; where is the support today? Is this thing looking to finish next week around 17.50? Open interest for October 18 options suggest a lot of people will be disappointed if this does not get back to 20 by then.

: - {

Right now, finishing at 15 next week is again a possibility. That, too, would be disappointing to many here.

Traders would probably file this under "buy the rumor, sell the news." Or buy before the conference; sell into the conference.
👍️0
TechandBio TechandBio 2 월 전
The pipeline is being overlooked Developing Transformative Cell and Exosome-based Therapeutic is going to tremendous.

$CAPR
👍️0
GreedyAgorist GreedyAgorist 2 월 전
I do not know; seems to be resistance once we get the 21 handle.

20% correction yesterday. Over 18% pop this morning. Lost about half that gain since then. Definitely getting bounced around.

I'm going to have to be more nimble if I want to open any more short term option contracts. (Only ten days to go.)
👍️0
TechandBio TechandBio 2 월 전
CAPR I'm up 480% YTD haven't sold a share. Looking for more appreciation!

$CAPR
👍️0
Mercedes99 Mercedes99 2 월 전
$30.00 by Nov 15th
👍️0
XWAVXALMIMAN XWAVXALMIMAN 2 월 전
Volcano called iron 8/21. Catching up on older posts. When do we get to 30?
👍️0

최근 히스토리

NASDAQ
CAPR
Capricor Therapeutics
COIN
N3RDZUSD
N3RD.FINANCE
LSE
76SP
Sa Glob Suk 24
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유